RNLX(Delisted)
Renalytix·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 1
Significant Revenue Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RNLX
Renalytix Plc
A UK-based company that develops artificial intelligence-enabled vitro diagnostic solutions for kidney diseases
--
03/15/2018
07/17/2020
NASDAQ Stock Exchange
110
06-30
Depository Receipts (Ordinary Shares)
2 Leman Street, London, United Kingdom E1W 9US
--
Renalytix plc was incorporated on 15 March 2018 as a public limited company under the laws of England and Wales. The company is an in vitro diagnostic company with artificial intelligence capabilities that optimizes the clinical management of kidney disease to improve patient prognosis and reduce medical costs.
Company Financials
EPS
RNLX has released its 2024 Q3 earnings. EPS was reported at -0.08, versus the expected -0.07, missing expectations. The chart below visualizes how RNLX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RNLX has released its 2024 Q4 earnings report, with revenue of 586.00K, reflecting a YoY change of 13.13%, and net profit of -7.07M, showing a YoY change of 36.29%. The Sankey diagram below clearly presents RNLX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
